Early-stage clinical trial results presented at a major oncology symposium indicate that an experimental alpha-emitting radiopharmaceutical demonstrates encouraging antitumor activity and a manageable safety profile in patients with advanced metastatic prostate cancer. Findings from the Phase 1 TheraPb trial evaluated weekly administrations of 212Pb-ADVC001, a targeted therapeutic agent designed to deliver potent, localized radiation directly to prostate-specific membrane antigen-positive malignant lesions.
The clinical trial enrolled heavily pretreated patients who had exhausted standard hormonal therapies and conventional chemotherapy regimens. Data showed that weekly dosing of the lead-212 radioisotope conjugate resulted in meaningful reductions in prostate-specific antigen levels and visible tumor shrinkage on functional molecular imaging scans. Because alpha particles deposit high energy over extremely short cellular distances, the treatment inflicted lethal double-strand DNA fractures on cancer cells while sparing adjacent healthy bone marrow and organs.
Oncologists noted that the targeted therapy exhibited favorable tolerability, with low rates of severe hematologic toxicities typically associated with systemic radiotherapies. Following the promising preliminary efficacy and tolerability outcomes, clinical investigators are preparing dose-expansion cohorts to further determine optimal treatment schedules for subsequent Phase 2 trials.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.eurekalert.org/news-releases/1149334